Sign In
Buy ABUS
$4.34
-0.0700 (-1.59%)
At Close: Jul 31, 2026
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
07:00am, Tuesday, 25'th Feb 2025
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
03:40pm, Thursday, 30'th Jan 2025
Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19
Arbutus Provides 2025 Corporate and Financial Update
07:30am, Monday, 13'th Jan 2025
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
07:56am, Tuesday, 07'th Jan 2025
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-1
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
07:30am, Tuesday, 26'th Nov 2024
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
11:02am, Friday, 15'th Nov 2024
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Significantly greater mean declines in HBsAg levels (p
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Thursday, 14'th Nov 2024
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
02:52pm, Wednesday, 06'th Nov 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Wednesday, 06'th Nov 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
07:30am, Wednesday, 23'rd Oct 2024
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
08:16am, Tuesday, 15'th Oct 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensiv
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
10:47am, Wednesday, 25'th Sep 2024
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Tuesday, 03'rd Sep 2024
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 22'nd Aug 2024
Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
